| Mineralocorticoid Receptor Antagonism in Heart Failure and Chronic Kidney Disease: Short-Term Pain for Long-Term Gain CJ Ferro, JN Townend Journal of the American College of Cardiology 83 (24), 2437-2439, 2024 | | 2024 |
| Coronary atherosclerotic plaque activity and risk of myocardial infarction KL Wang, C Balmforth, MN Meah, M Daghem, AJ Moss, E Tzolos, ... Journal of the American College of Cardiology 83 (22), 2135-2144, 2024 | 2 | 2024 |
| BS24 Establishing a clinically relevant progressive model of ckd-associated cardiomyopathy in mice for insights into early-stage pathogenesis A Hayes, K Bruce, M Sagmeister, J Townend, C Ferro, GA Ng, C O’Shea, ... Heart 110 (Suppl 3), A262-A263, 2024 | | 2024 |
| C Mechanisms of arrhythmia in fabry disease–A mixed in-vitro and in-vivo model A Roy, C O’Shea, M Cumberland, J Townend, T Geberhiwot, K Gehmlich, ... Heart 110 (Suppl 3), A289-A289, 2024 | | 2024 |
| Prevalence and Impact of Concomitant Atrial Fibrillation in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction I Shakeel, H Sharma, J Hodson, H Iqbal, R Tashfeen, PF Ludman, ... Journal of Clinical Medicine 13 (8), 2318, 2024 | | 2024 |
| Impact of antiplatelet therapy on microvascular thrombosis during ST-elevation myocardial infarction S Khattak, JN Townend, MR Thomas Frontiers in Molecular Biosciences 11, 1287553, 2024 | | 2024 |
| Health economic analysis IS Mackenzie, CJ Hawkey, I Ford, N Greenlaw, F Pigazzani, A Rogers, ... Allopurinol and cardiovascular outcomes in patients with ischaemic heart …, 2024 | | 2024 |
| Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation. IS Mackenzie, CJ Hawkey, I Ford, N Greenlaw, F Pigazzani, A Rogers, ... Health Technology Assessment (Winchester, England) 28 (18), 1, 2024 | 1 | 2024 |
| Heart disease and stroke statistics 2023 update from the American Heart Association—implications for nephrology NC Edwards, CJ Ferro, JN Townend Nephrology Dialysis Transplantation 39 (3), 387-394, 2024 | | 2024 |
| Early atrial remodelling drives arrhythmia in Fabry Disease A Roy, C O'Shea, A Dasi, L Patel, M Cumberland, D Nieves, ... bioRxiv, 2024.08. 13.607853, 2024 | | 2024 |
| Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis CS Kwok, CH Choy, J Pinney, JN Townend, C Whelan, M Fontana, ... ESC heart failure, 2024 | | 2024 |
| Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelines NC Edwards, AM Price, RP Steeds, CJ Ferro, JN Townend Nephrology Dialysis Transplantation 38 (8), 1798-1806, 2023 | 10 | 2023 |
| Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype C Hall, JP Law, JS Reyat, MJ Cumberland, S Hang, NTN Vo, K Raniga, ... Scientific Reports 13 (1), 12137, 2023 | 6 | 2023 |
| Improved adherence to guideline-recommended treatments in a specialist preventative pharmacology clinic compared to standard cardiology clinics after an acute coronary syndrome MR Thomas, N Desai, N Khan, O Hargreaves, A Khashaba, S Khattak, ... European Journal of Preventive Cardiology 30 (Supplement_1), zwad125. 125, 2023 | | 2023 |
| Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations JP Law, L Pickup, D Pavlovic, JN Townend, CJ Ferro Journal of Human Hypertension 37 (1), 1-19, 2023 | 52 | 2023 |
| Long term activation of human cardiac fibroblasts in 2D culture is irreversible C Hall, J Law, J Reyat, M Cumberland, C Weston, J Townend, C Ferro, ... Journal of Molecular and Cellular Cardiology 173, S36-S37, 2022 | | 2022 |
| Fibroblast growth factor 23 shortens left ventricular action potential duration and increases arrhythmogenicity J Law, S Kabir, C O'Shea, L Gallagher, J Morgan, W Chua, J Townend, ... Journal of Molecular and Cellular Cardiology 173, S80-S81, 2022 | | 2022 |
| Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month … NR Hill, D Lasserson, B Thompson, R Perera-Salazar, J Wolstenholme, ... Trials 23 (1), 999, 2022 | 1 | 2022 |
| Post-donation Haemodynamic Consequences AM Price, CJ Ferro, JN Townend Living Kidney Donation: A Practical Guide, 205-220, 2022 | | 2022 |
| Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial IS Mackenzie, CJ Hawkey, I Ford, N Greenlaw, F Pigazzani, A Rogers, ... The Lancet 400 (10359), 1195-1205, 2022 | 97 | 2022 |
